CC BY-NC-ND 4.0 · Laryngo-Rhino-Otol 2018; 97(S 01): S114-S141
DOI: 10.1055/s-0043-121964
Eigentümer und Copyright ©Georg Thieme Verlag KG 2018

Radiomics: Big Data Instead of Biopsies in the Future?

Article in several languages: deutsch | English
Kathrin Scheckenbach
1  Klinik für Hals-Nasen-Ohrenheilkunde, Universitätsklinikum Düsseldorf
› Author Affiliations
Further Information

Publication History

Publication Date:
22 March 2018 (online)



Precision medicine is increasingly pushed forward, also with respect to upcoming new targeted therapies. Individual characterization of diseases on the basis of biomarkers is a prerequisite for this development. So far, biomarkers are characterized clinically, histologically or on a molecular level. The implementation of broad screening methods (“Omics”) and the analysis of big data – in addition to single markers – allow to define biomarker signatures. Next to “Genomics”, “Proteomics”, and “Metabolicis”, “Radiomics” gained increasing interest during the last years. Based on radiologic imaging, multiple radiomic markers are extracted with the help of specific algorithms. These are correlated with clinical, (immuno-) histopathological, or genomic data. Underlying structural differences are based on the imaging metadata and are often not visible and therefore not detectable without specific software. Radiomics are depicted numerically or by graphs. The fact that radiomic information can be extracted from routinely performed imaging adds a specific appeal to this method. Radiomics could potentially replace biopsies and additional investigations. Alternatively, radiomics could complement other biomarkers and thus lead to a more precise, multimodal prediction. Until now, radiomics are primarily used to investigate solid tumors. Some promising studies in head and neck cancer have already been published.